Saquinavir mesylate (BioDeep_00000743404)

   

Volatile Flavor Compounds


代谢物信息卡片


Saquinavir mesylate

化学式: C39H54N6O8S (766.3723644000002)
中文名称: 甲磺酸沙奎那韦
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O.CS(=O)(=O)O
InChI: /m0./s1

描述信息

D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065692 - Cytochrome P-450 CYP3A Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor
C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors

同义名列表

2 个代谢物同义名

Saquinavir mesylate; Saquinavir mesylate



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Patrick Knoll, Nikolas Hörmann, Nguyet-Minh Nguyen Le, Richard Wibel, Ronald Gust, Andreas Bernkop-Schnürch. Charge converting nanostructured lipid carriers containing a cell-penetrating peptide for enhanced cellular uptake. Journal of colloid and interface science. 2022 Dec; 628(Pt A):463-475. doi: 10.1016/j.jcis.2022.07.160. [PMID: 35932682]
  • Denio A Ridjab, Ignatius Ivan, Fanny Budiman, Dwi Jani Juliawati. Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review. Medicine. 2021 Aug; 100(31):e26787. doi: 10.1097/md.0000000000026787. [PMID: 34397829]
  • Alireza Jalalvand, Somayeh Behjat Khatouni, Zahra Bahri Najafi, Foroozan Fatahinia, Narges Ismailzadeh, Behrokh Farahmand. Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method. Journal of basic and clinical physiology and pharmacology. 2021 Jul; 33(1):85-95. doi: 10.1515/jbcpp-2020-0369. [PMID: 34265888]
  • Yusuke Tanaka, Tri-Hung Nguyen, Estelle J A Suys, Christopher J H Porter. Digestion of Lipid-Based Formulations Not Only Mediates Changes to Absorption of Poorly Soluble Drugs Due to Differences in Solubilization But Also Reflects Changes to Thermodynamic Activity and Permeability. Molecular pharmaceutics. 2021 04; 18(4):1768-1778. doi: 10.1021/acs.molpharmaceut.1c00015. [PMID: 33729806]
  • Estelle J A Suys, Daniel H S Brundel, David K Chalmers, Colin W Pouton, Christopher J H Porter. Interaction with biliary and pancreatic fluids drives supersaturation and drug absorption from lipid-based formulations of low (saquinavir) and high (fenofibrate) permeability poorly soluble drugs. Journal of controlled release : official journal of the Controlled Release Society. 2021 03; 331(?):45-61. doi: 10.1016/j.jconrel.2021.01.007. [PMID: 33450318]
  • Sekhar Talluri. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19. Combinatorial chemistry & high throughput screening. 2021; 24(5):716-728. doi: 10.2174/1386207323666200814132149. [PMID: 32798373]
  • Martiniano Bello, Alberto Martínez-Muñoz, Irving Balbuena-Rebolledo. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA. Journal of molecular modeling. 2020 Nov; 26(12):340. doi: 10.1007/s00894-020-04600-4. [PMID: 33184722]
  • Teruhisa S Komatsu, Noriaki Okimoto, Yohei M Koyama, Yoshinori Hirano, Gentaro Morimoto, Yousuke Ohno, Makoto Taiji. Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation. Scientific reports. 2020 10; 10(1):16986. doi: 10.1038/s41598-020-74099-5. [PMID: 33046764]
  • Zhilong Jia, Xinyu Song, Jinlong Shi, Weidong Wang, Kunlun He. Transcriptome-based drug repositioning for coronavirus disease 2019 (COVID-19). Pathogens and disease. 2020 06; 78(4):. doi: 10.1093/femspd/ftaa036. [PMID: 32667665]
  • Donald C Hall, Hai-Feng Ji. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel medicine and infectious disease. 2020 May; 35(?):101646. doi: 10.1016/j.tmaid.2020.101646. [PMID: 32294562]
  • Francesca L Wood, J Brian Houston, David Hallifax. Importance of the Unstirred Water Layer and Hepatocyte Membrane Integrity In Vitro for Quantification of Intrinsic Metabolic Clearance. Drug metabolism and disposition: the biological fate of chemicals. 2018 03; 46(3):268-278. doi: 10.1124/dmd.117.078949. [PMID: 29233818]
  • Dengning Xia, Yuan He, Qiuxia Li, Cunde Hu, Wei Huang, Yunhai Zhang, Feng Wan, Chi Wang, Yong Gan. Transport mechanism of lipid covered saquinavir pure drug nanoparticles in intestinal epithelium. Journal of controlled release : official journal of the Controlled Release Society. 2018 01; 269(?):159-170. doi: 10.1016/j.jconrel.2017.11.012. [PMID: 29129657]
  • Mingzhu He, Kai Fan Cheng, Sonya VanPatten, Ona Bloom, Betty Diamond, Yousef Al-Abed. A structural investigation of FISLE-412, a peptidomimetic compound derived from saquinavir that targets lupus autoantibodies. Bioorganic & medicinal chemistry letters. 2017 10; 27(20):4725-4729. doi: 10.1016/j.bmcl.2017.08.070. [PMID: 28927788]
  • Xin Wang, Renlingzi Zhang, Yao Tong, Xibing Ding, Shuqing Jin, Xiang Zhao, Jiaying Zong, Zhixia Chen, Timothy R Billiar, Quan Li. High-mobility group box 1 protein is involved in the protective effect of Saquinavir on ventilation-induced lung injury in mice. Acta biochimica et biophysica Sinica. 2017 Oct; 49(10):907-915. doi: 10.1093/abbs/gmx085. [PMID: 28981603]
  • Qiuxia Li, Dengning Xia, Jinsong Tao, Aijun Shen, Yuan He, Yong Gan, Chi Wang. Self-Assembled Core-Shell-Type Lipid-Polymer Hybrid Nanoparticles: Intracellular Trafficking and Relevance for Oral Absorption. Journal of pharmaceutical sciences. 2017 10; 106(10):3120-3130. doi: 10.1016/j.xphs.2017.05.029. [PMID: 28559042]
  • A Polus, M Bociaga-Jasik, U Czech, J Goralska, U Cialowicz, M Chojnacka, M Polus, K Jurowski, A Dembinska-Kiec. The human immunodeficiency virus (HIV1) protease inhibitor sanquinavir activates autophagy and removes lipids deposited in lipid droplets. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2017 Apr; 68(2):283-293. doi: ". [PMID: 28614778]
  • Thiago Caon, Jadel Muller Kratz, Gislaine Kuminek, Melina Heller, Gustavo Amadeu Micke, Bibiana Verlindo de Araujo, Letícia Scherer Koester, Cláudia Maria Oliveira Simões. Pharmacokinetics of Saquinavir Mesylate from Oral Self-Emulsifying Lipid-Based Delivery Systems. European journal of drug metabolism and pharmacokinetics. 2017 Feb; 42(1):135-141. doi: 10.1007/s13318-016-0321-x. [PMID: 26846485]
  • Sanelisiwe Nzuza, Sindiswa Zondi, Peter M O Owira. Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo. PloS one. 2017; 12(11):e0183355. doi: 10.1371/journal.pone.0183355. [PMID: 29121676]
  • J Li, Y Liu, X Yu, J Zhang, J Gu, L Zhao. Reduced Oral Bioavailability and Altered Pharmacokinetics of Saquinavir by Co-administration with Biochanin A in Rats. Drug research. 2016 Sep; 66(9):484-488. doi: 10.1055/s-0042-110393. [PMID: 27409329]
  • Jiapeng Li, Yang Liu, Jingru Zhang, Xiaotong Yu, Xiaoling Wang, Libo Zhao. Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats. Drug design, development and therapy. 2016; 10(?):3699-3706. doi: 10.2147/dddt.s118723. [PMID: 27895462]
  • Marta Boffito, David Back, José M Gatell. Twenty years of boosting antiretroviral agents: where are we today?. AIDS (London, England). 2015 Nov; 29(17):2229-33. doi: 10.1097/qad.0000000000000800. [PMID: 26544697]
  • Graciela Cárdenas, M López-González, J F Monzón-Falconi, J L Soto-Hernández, D Perales-Martínez, C López-Vejar. Relation of cerebrospinal fluid/plasma HIV-RNA discordance with neurocognitive impairment. The National medical journal of India. 2015 Sep; 28(5):228-32. doi: NULL. [PMID: 27132951]
  • Yuan He, Deng-ning Xia, Qiu-xia Li, Jin-song Tao, Yong Gan, Chi Wang. Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation. Acta pharmacologica Sinica. 2015 Sep; 36(9):1151-60. doi: 10.1038/aps.2015.53. [PMID: 26256404]
  • Sterenn Davis, Benjamin M Davis, Joanna L Richens, Kelly-Ann Vere, Peter G Petrov, C Peter Winlove, Paul O'Shea. α-Tocopherols modify the membrane dipole potential leading to modulation of ligand binding by P-glycoprotein. Journal of lipid research. 2015 Aug; 56(8):1543-50. doi: 10.1194/jlr.m059519. [PMID: 26026069]
  • Emma Lawless, Brendan T Griffin, Aoife O'Mahony, Caitriona M O'Driscoll. Exploring the impact of drug properties on the extent of intestinal lymphatic transport - in vitro and in vivo studies. Pharmaceutical research. 2015 May; 32(5):1817-29. doi: 10.1007/s11095-014-1578-x. [PMID: 25428258]
  • Lakshmi Narashimhan Ramana, Shilpee Sharma, Swaminathan Sethuraman, Udaykumar Ranga, Uma Maheswari Krishnan. Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs--modern Trojan horses to combat HIV. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2015 Jan; 89(?):300-11. doi: 10.1016/j.ejpb.2014.11.021. [PMID: 25500283]
  • Nageswara Rao Ramisetti, Narendra Varma Nimmu, Gangu Naidu Challa. Ionic liquid-based dispersive liquid-liquid microextraction followed by RP-HPLC determination of saquinavir in rat serum: application to pharmacokinetics. Biomedical chromatography : BMC. 2014 Dec; 28(12):1874-80. doi: 10.1002/bmc.3237. [PMID: 24944096]
  • Christoph Hagen, Stephan Werner, Susana Carregal-Romero, Ashraf N Malhas, Barbara G Klupp, Peter Guttmann, Stefan Rehbein, Katja Henzler, Thomas C Mettenleiter, David J Vaux, Wolfgang J Parak, Gerd Schneider, Kay Grünewald. Multimodal nanoparticles as alignment and correlation markers in fluorescence/soft X-ray cryo-microscopy/tomography of nucleoplasmic reticulum and apoptosis in mammalian cells. Ultramicroscopy. 2014 Nov; 146(?):46-54. doi: 10.1016/j.ultramic.2014.05.009. [PMID: 24973653]
  • Ana Beloqui, María Ángeles Solinís, Anne des Rieux, Véronique Préat, Alicia Rodríguez-Gascón. Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. International journal of pharmaceutics. 2014 Jul; 468(1-2):105-11. doi: 10.1016/j.ijpharm.2014.04.027. [PMID: 24746410]
  • Hitendra S Mahajan, Milind S Mahajan, Pankaj P Nerkar, Anshuman Agrawal. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting. Drug delivery. 2014 Mar; 21(2):148-54. doi: 10.3109/10717544.2013.838014. [PMID: 24128122]
  • Feng Li, Jie Lu, Xiaochao Ma. CPY3A4-mediated α-hydroxyaldehyde formation in saquinavir metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2014 Feb; 42(2):213-20. doi: 10.1124/dmd.113.054874. [PMID: 24212380]
  • Yung-Chih Kuo, Cheng-Chin Wang. Cationic solid lipid nanoparticles with cholesterol-mediated surface layer for transporting saquinavir to the brain. Biotechnology progress. 2014 Jan; 30(1):198-206. doi: 10.1002/btpr.1834. [PMID: 24167123]
  • Ghaith Al-Jayyoussi, Daniel F Price, Danielle Francombe, Glyn Taylor, Mathew W Smith, Chris Morris, Chris D Edwards, Peter Eddershaw, Mark Gumbleton. Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: a study in ex vivo lung models using chemical inhibition and genetic knockout. Journal of pharmaceutical sciences. 2013 Sep; 102(9):3382-94. doi: 10.1002/jps.23587. [PMID: 23670704]
  • Yoshihisa Shitara, Kumiko Takeuchi, Toshiharu Horie. Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake. Journal of pharmaceutical sciences. 2013 Sep; 102(9):3427-35. doi: 10.1002/jps.23477. [PMID: 23440887]
  • Yung-Chih Kuo, Hsing-Fu Ko. Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles. Biomaterials. 2013 Jul; 34(20):4818-30. doi: 10.1016/j.biomaterials.2013.03.013. [PMID: 23545288]
  • Ichiro Ieiri, Shyohei Tsunemitsu, Kazuya Maeda, Yukie Ando, Noritomo Izumi, Miyuki Kimura, Naoe Yamane, Tsuyoshi Okuzono, Mariko Morishita, Naoki Kotani, Eri Kanda, Mariko Deguchi, Kyoko Matsuguma, Shunji Matsuki, Takeshi Hirota, Shin Irie, Hiroyuki Kusuhara, Yuichi Sugiyama. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. Journal of clinical pharmacology. 2013 Jun; 53(6):654-61. doi: 10.1002/jcph.62. [PMID: 23381882]
  • Kinam Park. Transport of nanostructured lipid carriers across the intestinal barrier. Journal of controlled release : official journal of the Controlled Release Society. 2013 Mar; 166(2):195. doi: 10.1016/j.jconrel.2013.01.024. [PMID: 23414558]
  • Ana Beloqui, María Ángeles Solinís, Alicia R Gascón, Ana del Pozo-Rodríguez, Anne des Rieux, Véronique Préat. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. Journal of controlled release : official journal of the Controlled Release Society. 2013 Mar; 166(2):115-23. doi: 10.1016/j.jconrel.2012.12.021. [PMID: 23266764]
  • Yung-Chih Kuo, Cheng-Chin Wang. Cationic solid lipid nanoparticles with primary and quaternary amines for release of saquinavir and biocompatibility with endothelia. Colloids and surfaces. B, Biointerfaces. 2013 Jan; 101(?):101-5. doi: 10.1016/j.colsurfb.2012.06.002. [PMID: 22796778]
  • Atsuko Tomaru, Mariko Takeda-Morishita, Hirokazu Banba, Kozo Takayama. Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice. Drug metabolism and pharmacokinetics. 2013; 28(2):144-52. doi: 10.2133/dmpk.dmpk-12-rg-057. [PMID: 22971642]
  • Monika Bociąga-Jasik, Anna Polus, Joanna Góralska, Urszula Czech, Anna Gruca, Agnieszka Śliwa, Aleksander Garlicki, Tomasz Mach, Aldona Dembińska-Kieć. Metabolic effects of the HIV protease inhibitor--saquinavir in differentiating human preadipocytes. Pharmacological reports : PR. 2013; 65(4):937-50. doi: 10.1016/s1734-1140(13)71075-2. [PMID: 24145088]
  • Zhiying Wang, Dhananjay Pal, Ashim K Mitra. Stereoselective evasion of P-glycoprotein, cytochrome P450 3A, and hydrolases by peptide prodrug modification of saquinavir. Journal of pharmaceutical sciences. 2012 Sep; 101(9):3199-213. doi: 10.1002/jps.23193. [PMID: 22611042]
  • Yung-Chih Kuo, Chiu-Yen Chung. Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir. Colloids and surfaces. B, Biointerfaces. 2011 Dec; 88(2):682-90. doi: 10.1016/j.colsurfb.2011.07.060. [PMID: 21865017]
  • Maria Martinez-Rebollar, Montserrat Lonca, Iñaki Perez, Dolors Soy, Mercè Brunet, Rosa Martin, Oriol Coll, Sandra Hernandez, Montserrat Laguno, Ana Milinkovic, Maria Larrousse, Marta Calvo, Jose L Blanco, Esteban Martínez, Jose M Gatell, Josep Mallolas. Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women. Therapeutic drug monitoring. 2011 Dec; 33(6):772-7. doi: 10.1097/ftd.0b013e318236376d. [PMID: 22105596]
  • S M E Vrouenraets, F W N M Wit, E Fernandez Garcia, G J Moyle, A G Jackson, C Allavena, F Raffi, D T Jayaweera, S Mauss, C Katlama, M Fisher, L Slama, W D Hardy, E Dejesus, A van Eeden, P Reiss. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients. HIV medicine. 2011 Nov; 12(10):620-31. doi: 10.1111/j.1468-1293.2011.00941.x. [PMID: 21819530]
  • Filippo Canducci, Elisa Rita Ceresola, Diego Saita, Yousef Al-Abed, Gianni Garotta, Massimo Clementi, Ferdinando Nicoletti. The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir. Antiviral research. 2011 Sep; 91(3):292-5. doi: 10.1016/j.antiviral.2011.07.001. [PMID: 21763726]
  • Chiara Tommasi, Rita Bellagamba, Massimo Tempestilli, Antonio D'Avolio, Anna L Gallo, Jelena Ivanovic, Emanuele Nicastri, Leopoldo P Pucillo, Pasquale Narciso. Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis. Malaria journal. 2011 May; 10(?):141. doi: 10.1186/1475-2875-10-141. [PMID: 21600016]
  • Patrice Muret, Caroline Solas. [Evidence-based therapeutic drug monitoring for saquinavir]. Therapie. 2011 May; 66(3):207-12. doi: NULL. [PMID: 21819804]
  • H Knechten, C Stephan, F A Mosthaf, H Jaeger, A Carganico, T Lutz, K Schewe, C Mayr, E Wolf, E Wellmann, A Tappe. The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients. European journal of medical research. 2011 Mar; 16(3):93-100. doi: 10.1186/2047-783x-16-3-93. [PMID: 21486721]
  • Miriam Gyalrong-Steur, J R Bogner, U Seybold. Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients. European journal of medical research. 2011 Feb; 16(2):85-92. doi: 10.1186/2047-783x-16-2-85. [PMID: 21463988]
  • R Lledó-García, A Nácher, V G Casabó, M Merino-Sanjuán. A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat. Drug metabolism and disposition: the biological fate of chemicals. 2011 Feb; 39(2):294-301. doi: 10.1124/dmd.110.034488. [PMID: 20978105]
  • Xiaoping Zhang, Scott Fettner, Elke Zwanziger, Lucy Rowell, Miklos Salgo. Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects. Antimicrobial agents and chemotherapy. 2011 Feb; 55(2):680-7. doi: 10.1128/aac.00992-10. [PMID: 21135186]
  • Shamsunder S Dodiya, Sandip S Chavhan, Krutika K Sawant, Aruna G Korde. Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies. Journal of microencapsulation. 2011; 28(6):515-27. doi: 10.3109/02652048.2011.590612. [PMID: 21728760]
  • Elena Toschi, Cecilia Sgadari, Laura Malavasi, Ilaria Bacigalupo, Chiara Chiozzini, Davide Carlei, Daniela Compagnoni, Stefania Bellino, Roberto Bugarini, Mario Falchi, Clelia Palladino, Patrizia Leone, Giovanni Barillari, Paolo Monini, Barbara Ensoli. Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases. International journal of cancer. 2011 Jan; 128(1):82-93. doi: 10.1002/ijc.25550. [PMID: 20617515]
  • Gustavo A Yerino, Emilia K Halabe, Elvira Zini, Ethel C Feleder. Bioequivalence study of two oral tablet formulations containing saquinavir mesylate boosted with ritonavir in healthy male subjects. Arzneimittel-Forschung. 2011; 61(8):481-7. doi: 10.1055/s-0031-1296231. [PMID: 21950153]
  • Katja Berginc, Albin Kristl. Transwell-grown HepG2 cell monolayers as in vitro permeability model to study drug-drug or drug-food interactions. Journal of medicinal food. 2011 Jan; 14(1-2):135-9. doi: 10.1089/jmf.2010.0041. [PMID: 21138349]
  • Alan Kennedy, Martina Hennessy, Colm Bergin, Fiona Mulcahy, Susan Hopkins, J Paul Spiers. Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients. Antiviral therapy. 2011; 16(8):1237-47. doi: 10.3851/imp1867. [PMID: 22155905]
  • Jacek Hajda, Katharina M Rentsch, Christoph Gubler, Hans Steinert, Bruno Stieger, Karin Fattinger. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2010 Dec; 41(5):729-35. doi: 10.1016/j.ejps.2010.09.016. [PMID: 20933082]
  • Bilge Diker, Omar Janneh, Rolf P G van Heeswijk, Karen F T Copeland. Comparative efflux of saquinavir, ritonavir and lopinavir from primary human cells. Drug metabolism letters. 2010 Dec; 4(4):241-5. doi: 10.2174/187231210792928297. [PMID: 20690898]
  • Shriram M Pathak, Prashant Musmade, Swapnil Dengle, Arumugam Karthik, Krishnamurthy Bhat, Nayanabhirama Udupa. Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-Preparation and in vitro and in vivo evaluation. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2010 Nov; 41(3-4):440-51. doi: 10.1016/j.ejps.2010.07.013. [PMID: 20656025]
  • Katja Berginc, Tina Trdan, Jurij Trontelj, Albin Kristl. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy. Biopharmaceutics & drug disposition. 2010 Nov; 31(8-9):495-505. doi: 10.1002/bdd.730. [PMID: 21104925]
  • C Stephan, H Jaeger, A Carganico, G Knecht, T Lutz, C Mayr, F A Mosthaf, S Koeppe, M Mueller, E Wolf, A Tappe, E Wellmann, H Knechten. Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients. European journal of medical research. 2010 Sep; 15(9):369-76. doi: 10.1186/2047-783x-15-9-369. [PMID: 20952345]
  • Echeverria Patricia, Pere Domingo, Mar Gutierrez, Mateo Gracia, Monse Fuster, José Molto, Jordi Puig, Nuria Perez-Alvarez, Bonaventura Clotet, Eugenia Negredo. Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients. Current HIV research. 2010 Sep; 8(6):467-70. doi: 10.2174/157016210793499358. [PMID: 20636275]
  • Yung-Chih Kuo, Hung-Hao Chen. Effect of electromagnetic field on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells. Journal of drug targeting. 2010 Jul; 18(6):447-56. doi: 10.3109/10611860903494245. [PMID: 20528098]
  • Gregory J Anger, Micheline Piquette-Miller. Impact of hyperlipidemia on plasma protein binding and hepatic drug transporter and metabolic enzyme regulation in a rat model of gestational diabetes. The Journal of pharmacology and experimental therapeutics. 2010 Jul; 334(1):21-32. doi: 10.1124/jpet.110.165639. [PMID: 20348205]
  • H Knechten, C Stephan, F A Mosthaf, H Jaeger, T Lutz, A Cargnico, A Stoehr, S Koeppe, C Mayr, K Schewe, E Wolf, E Wellmann, A Tappe. Safety and efficacy of a saquinavir-containing antiretroviral regimen in previously ART-naïve or pretreated but protease inhibitor-naïve HIV-positive patients. Infection. 2010 Apr; 38(2):108-16. doi: 10.1007/s15010-009-9249-x. [PMID: 20352287]
  • Martin S Rhee, James A Hellinger, Sandy Sheble-Hall, Calvin J Cohen, David J Greenblatt. Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir). Journal of clinical pharmacology. 2010 Apr; 50(4):392-400. doi: 10.1177/0091270009339739. [PMID: 20097936]
  • C Schmitt, B Kaeser, M Riek, N Bech, C Kreuzer. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. International journal of clinical pharmacology and therapeutics. 2010 Mar; 48(3):192-9. doi: 10.5414/cpp48192. [PMID: 20197013]
  • Eskild Petersen, Huiling Mu, Trine Porsgaard, Lone S Bertelsen. The protease inhibitors ritonavir and saquinavir influence lipid metabolism: a pig model for the rapid evaluation of new drugs. Antiviral therapy. 2010; 15(2):243-51. doi: 10.3851/imp1509. [PMID: 20386080]
  • Katja Berginc, Irina Milisav, Albin Kristl. Garlic flavonoids and organosulfur compounds: impact on the hepatic pharmacokinetics of saquinavir and darunavir. Drug metabolism and pharmacokinetics. 2010; 25(6):521-30. doi: 10.2133/dmpk.dmpk-10-rg-053. [PMID: 20930421]
  • Katja Berginc, Jurij Trontelj, Albin Kristl. The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices. Drug metabolism and pharmacokinetics. 2010; 25(3):307-13. doi: 10.2133/dmpk.25.307. [PMID: 20610890]
  • M Bickel, A Bodtländer, G K Knecht, C Stephan, N von Hentig, M Kurowski, P Gute, S Klauke, T Lutz. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients. The Journal of antimicrobial chemotherapy. 2009 Dec; 64(6):1260-4. doi: 10.1093/jac/dkp348. [PMID: 19776037]
  • Upal Roy, Geetika Chakravarty, Kerstin Honer Zu Bentrup, Debasis Mondal. Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir. Biological & pharmaceutical bulletin. 2009 Dec; 32(12):2002-9. doi: 10.1248/bpb.32.2002. [PMID: 19952419]
  • Christophe Schmitt, Carsten Hofmann, Myriam Riek, Arpna Patel, Elke Zwanziger. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy. 2009 Oct; 29(10):1175-81. doi: 10.1592/phco.29.10.1175. [PMID: 19792991]
  • Lisa D Coles, Insong J Lee, Hazem E Hassan, Natalie D Eddington. Distribution of saquinavir, methadone, and buprenorphine in maternal brain, placenta, and fetus during two different gestational stages of pregnancy in mice. Journal of pharmaceutical sciences. 2009 Aug; 98(8):2832-46. doi: 10.1002/jps.21644. [PMID: 19116954]
  • Candice Jamois, Patrick Smith, Royce Morrison, Myriam Riek, Arpna Patel, Christophe Schmitt, Peter N Morcos, Xiaoping Zhang. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy. Addiction biology. 2009 Jul; 14(3):321-7. doi: 10.1111/j.1369-1600.2009.00158.x. [PMID: 19523046]
  • Jasper van der Lugt, Meena Gorowara, Anchalee Avihingsanon, David Burger, Jintanat Ananworanich, Kancharat Sringam, Stephen Kerr, Ferdinand Wit, Joep Lange, Kiat Ruxrungtham. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals. AIDS (London, England). 2009 Jun; 23(9):1176-9. doi: 10.1097/qad.0b013e32832b4461. [PMID: 19451794]
  • Jane M Sayer, John M Louis. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin. Proteins. 2009 May; 75(3):556-68. doi: 10.1002/prot.22271. [PMID: 18951411]
  • José Moltó, Josep Maria Llibre, Esteban Ribera, Carlos Mínguez, Jesús Sánchez del Río, Enric Pedrol, Gabriel Vallecillo, Samandhy Cedeño, Marta Valle, Cristina Miranda, Eugenia Negredo, Bonaventura Clotet. Saquinavir exposure in HIV-infected patients with chronic viral hepatitis. The Journal of antimicrobial chemotherapy. 2009 May; 63(5):992-7. doi: 10.1093/jac/dkp070. [PMID: 19279052]
  • Surabhi Chandra, Debasis Mondal, Krishna C Agrawal. HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone. Experimental biology and medicine (Maywood, N.J.). 2009 Apr; 234(4):442-53. doi: 10.3181/0811-rm-317. [PMID: 19234050]
  • Sharon Walmsley, Anchalee Avihingsanon, Jihad Slim, Douglas J Ward, Kiat Ruxrungtham, Jason Brunetta, U Fritz Bredeek, Dushyantha Jayaweera, Carol Jean Guittari, Peter Larson, Malte Schutz, François Raffi. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. Journal of acquired immune deficiency syndromes (1999). 2009 Apr; 50(4):367-74. doi: 10.1097/qai.0b013e318198a815. [PMID: 19214123]
  • Yung-Chih Kuo, Hung-Hao Chen. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. International journal of pharmaceutics. 2009 Jan; 365(1-2):206-13. doi: 10.1016/j.ijpharm.2008.08.050. [PMID: 18848610]
  • Jasper van der Lugt, Angela Colbers, Jose Molto, David Hawkins, Marchina van der Ende, Martin Vogel, Christoph Wyen, Malte Schutz, Peter Koopmans, Kiat Ruxrungtham, Clemens Richter, David Burger. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women. Antiviral therapy. 2009; 14(3):443-50. doi: NULL. [PMID: 19474478]
  • Laure Elens, Sophie Veriter, Vincent Di Fazio, Roger Vanbinst, Daniel Boesmans, Pierre Wallemacq, Vincent Haufroid. Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection. Clinical chemistry. 2009 Jan; 55(1):170-4. doi: 10.1373/clinchem.2008.108647. [PMID: 19028822]
  • Torsak Bunupuradah, Jasper van der Lugt, Pope Kosalaraksa, Chulapan Engchanil, Pitch Boonrak, Thanyawee Puthanakit, Tawan Mengthaisong, Apicha Mahanontharit, Pagakrong Lumbiganon, Emily Tompkins, David Burger, Kiat Ruxrungtham, Jintanat Ananworanich. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. Antiviral therapy. 2009; 14(2):241-8. doi: NULL. [PMID: 19430099]
  • Laura Dickinson, Marta Boffito, David J Back, Saye H Khoo, Anton L Pozniak, Peter Mugyenyi, Concepta Merry, Reshma Saskia Autar, David M Burger, Leon J Aarons. Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. The Journal of antimicrobial chemotherapy. 2008 Dec; 62(6):1344-55. doi: 10.1093/jac/dkn399. [PMID: 18824460]
  • R M López Galera, E Ribera Pascuet, J I Esteban Mur, J B Montoro Ronsano, J C Juárez Giménez. Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir. European journal of clinical pharmacology. 2008 Dec; 64(12):1235-6. doi: 10.1007/s00228-008-0551-1. [PMID: 18712519]
  • Clara Lehmann, Norma Jung, Anika Hofmann, Oliver A Cornely, Christoph Wyen, Gerd Fätkenheuer, Pia Hartmann. Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression. Current HIV research. 2008 Nov; 6(6):555-9. doi: 10.2174/157016208786501526. [PMID: 18991621]
  • Michel Wagner, Emmanuel Varesio, Gérard Hopfgartner. Ultra-fast quantitation of saquinavir in human plasma by matrix-assisted laser desorption/ionization and selected reaction monitoring mode detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2008 Sep; 872(1-2):68-76. doi: 10.1016/j.jchromb.2008.07.009. [PMID: 18657486]
  • Pope Kosalaraksa, Torsak Bunupuradah, Chulapan Engchanil, Pitch Boonrak, Jintana Intasan, Pagakrong Lumbiganon, David Burger, Kiat Ruxrungtham, Malte Schutz, Jintanat Ananworanich. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. The Pediatric infectious disease journal. 2008 Jul; 27(7):623-8. doi: 10.1097/inf.0b013e31816b4539. [PMID: 18520443]
  • Laura Dickinson, Marta Boffito, Saye H Khoo, Malte Schutz, Leon J Aarons, Anton L Pozniak, David J Back. Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. The Journal of antimicrobial chemotherapy. 2008 Jul; 62(1):161-7. doi: 10.1093/jac/dkn187. [PMID: 18467305]
  • K Singh, L Dickinson, A Chaikan, D Back, C Fletcher, A Pozniak, G Moyle, M Nelson, B Gazzard, D Herath, M Boffito. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. Clinical pharmacology and therapeutics. 2008 Jun; 83(6):867-72. doi: 10.1038/sj.clpt.6100375. [PMID: 17898705]
  • Brendan T Griffin, Caitriona M O'Driscoll. An examination of the effect of intestinal first pass extraction on intestinal lymphatic transport of saquinavir in the rat. Pharmaceutical research. 2008 May; 25(5):1125-33. doi: 10.1007/s11095-007-9473-3. [PMID: 17975709]
  • Helen H Usansky, Peidi Hu, Patrick J Sinko. Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats. Drug metabolism and disposition: the biological fate of chemicals. 2008 May; 36(5):863-9. doi: 10.1124/dmd.107.017483. [PMID: 18256206]
  • Yung-Chih Kuo, Chan-Ying Kuo. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. International journal of pharmaceutics. 2008 Mar; 351(1-2):271-81. doi: 10.1016/j.ijpharm.2007.09.020. [PMID: 17976933]
  • Tushar K Vyas, Aliasgar Shahiwala, Mansoor M Amiji. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. International journal of pharmaceutics. 2008 Jan; 347(1-2):93-101. doi: 10.1016/j.ijpharm.2007.06.016. [PMID: 17651927]
  • Nils von Hentig, Gabi Nisius, Tessa Lennemann, Pavel Khaykin, Christoph Stephan, Errol Babacan, Schlomo Staszewski, Michael Kurowski, Sebastian Harder, Annette Haberl. Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. Antiviral therapy. 2008; 13(8):1039-46. doi: NULL. [PMID: 19195329]
  • Weerawat Manosuthi, Somnuek Sungkanuparph, Kiat Ruxrungtham, Wisit Prasithsirikul, Chatiya Athichathanabadi, Woraphot Tantisiriwat, Chureeratana Bowonwatanuwong, Nopphanath Chumpathat, Achara Chaovavanich. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir. Journal of acquired immune deficiency syndromes (1999). 2008 Jan; 47(1):127-9. doi: 10.1097/qai.0b013e318157b0da. [PMID: 18156994]
  • Tomasz Pawiński, Piotr Pulik, Beata Gralak, Andrzej Horban. Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy. Acta poloniae pharmaceutica. 2008 Jan; 65(1):93-100. doi: NULL. [PMID: 18536180]